Skip to main content
Premium Trial:

Request an Annual Quote

Rennova Health, Certainty Health Partner on Mobile PGx Platform

NEW YORK (GenomeWeb) – Rennova Health announced today that it has partnered with Certainty Health to develop a smartphone-based platform to offer molecular tests enabling the precision treatment of psychiatric disorders.

Under the terms of the deal, Rennova will offer genetic tests — developed by its subsidiary Advanced Molecular Services (AMS) Group under the Certainty Health brand — directly to consumers via a mobile platform. The first tests will include ones that can help determine how an individual may respond to various drugs used to treat psychiatric disorders.

Rennova said that the general availability of the platform and online ordering of its molecular tests is expected by the fourth quarter of 2017. Additional terms were not disclosed.

"Today the cost of and access to these tests is prohibitive to the people who need it most," AMS Group CEO Scott Jenkins said in a statement. "Modern e-commerce and mobile tools will bring immediate access to these life-changing diagnostics and tools to everyone."

Rennova formed AMS Group earlier this year through a merger of three of its subsidiaries: CollabRx, a clinical decision-support company that merged with Medytox Solutions in 2015 to become Rennova; Genomas, a pharmacogenomics testing firm Rennova fully acquired last year; and Alethea Laboratories, which Medytox acquired in early 2013.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.